John Dellapa, a corporate lawyer, has become general counsel at Neurimmune AG of Switzerland having previously advised the neuroscience company on a number of global transactions. Neurimmune has a late-stage drug candidate for Alzheimer’s disease and is investigating therapies for a number of other neurological diseases. Mr Dellapa was previously a lawyer with the Boston, US office of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo. Prior to this, he was general counsel at Fisher Scientific International Inc. He holds a Juris Doctor degree from George Washington University and a Bachelor’s degree in management from Boston College, both in the US.
Neurimmune announced the appointment on 1 March 2019.
Copyright 2019 Evernow Publishing Ltd
